Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Vertex Pharmaceuticals Incorporated To Contact the Firm
NEW YORK, Oct. 13, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") (NasdaqGS: VRTX).
The investigation focuses on whether the Company and its executives violated federal securities laws by misrepresenting the results of its Phase 2 study of its experimental drugs VX-909 and Kalydeco in statements made on May 7, 2012 and May 29, 2012. On June 27, 2012 the Company admitted that those prior statements regarding the Phase 2 study were inaccurate and Vertex's stock price declined significantly on the news.
Request more information now by clicking here: www.faruqilaw.com/VRTX. There is no cost or obligation to you.
If you purchased Vertex stock or options between May 7, 2012 and June 27, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/VRTX. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Vertex's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.